Cardiovascular risk and lipid control in secondary prevention

Prevention of cardiovascular ischemic events: high-risk and secondary prevention.

Atherosclerosis is a chronic disease involving the coronary, carotid, and aorto-femoral vascular beds that represents the major cause of death worldwide.1,2 Coronary artery disease (CAD) is the major cause of morbidity and mortality in the world. Efforts at preventing the clinical manifestations of atherosclerosis have yielded impressive results in the past 3 decades and constitute the major fo...

[Secondary prevention program: impact on cardiovascular risk].

The aims of this study were to determine the effect of a secondary prevention program on the treatment and control of coronary risk factors and to assess whether it improves functional capacity. The study involved 401 patients with coronary heart disease (mean age 57.1 years; 89% men). Clinical and anthropometric data, including blood pressure, were recorded, and electrocardiography, laboratory...

Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease.

The Availability and Affordability of Cardiovascular Medicines for secondary prevention in Tehran Province

Abstract Abstract Background: Availability and affordability of medicines are crucial to achieving success in prevention programs, particularly in developing countries. Objective: The aim of this study was to determine the availability and affordability of cardiovascular medicines for secondary prevention in Tehran province of Iran. Methods: A cross-sectional survey was conducted in Tehran pro...

Reducing residual risk in secondary prevention of cardiovascular disease.

Prevention of cardiovascular disease (CVD) spans the human lifespan, including primordial, primary, and secondary prevention efforts. Extensive evidence from epidemiological, genetic, and animal studies confirms the central importance of elevated low-density lipoprotein (LDL) cholesterol (LDL-C) in atherosclerotic CVD events.1 The Cholesterol Treatment Trialists Collaboration provides perperson...